| B78 | Progression risk in people with HIV and COVID-19: predictive performance of current risk scores | E-poster | COVID-19 morbidity and mortality in PLWH |
| B78 | Characterizing the impact of COVID-19 among female sex workers living with HIV in Durban, South Africa | E-poster | COVID-19 morbidity and mortality in PLWH |
| B78 | Seroprevalence and risk factors of SARS-CoV-2 infection in people living with HIV | E-poster | COVID-19 morbidity and mortality in PLWH |
| B78 | Mortality COVID-19 in people living with HIV in a private insurance carrier in Colombia | E-poster | COVID-19 morbidity and mortality in PLWH |
| B78 | Impact of HIV on COVID-19 outcomes among hospitalized adults in the United States | E-poster | COVID-19 morbidity and mortality in PLWH |
| B78 | Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform | E-poster | COVID-19 morbidity and mortality in PLWH |
| B76 | Cardiometabolic risk factor comparison between foreign and native born African American persons with HIV infection in a U.S. urban healthcare setting | E-poster | Clinical issues in other vulnerable populations |
| B71 | Correlates of medication for opioid use disorder treatment retention in patients with HIV and opioid use disorder in Northern Viet Nam | E-poster | Clinical issues in people who use drugs |
| B7 | A rapid enzymatic assay for selective detection of HIV drugs that indicate long-term and short-term PrEP adherence | Oral abstract session with live Q&A | ART adherence measurement |
| B7 | No difference in urine tenofovir levels in patients living with HIV on unboosted vs dose-adjusted boosted tenofovir alafenamide | E-poster | ART adherence measurement |